NCT01962961已完成1 期
A Randomized, Placebo-Controlled Pilot Trial Assessing Two Doses of N-Acetylcysteine on Changes in Oxidative Stress and Endothelial Function in HIV-infected Older Adults Receiving Stable Antiretroviral Therapy
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 2
- 主要终点
- Change in Circulating F2-isoprostane Levels
研究概览
简要总结
The goal of this study is to determine if n-acetylcysteine, given as PharmaNAC, reduces oxidative stress and improves vascular function in HIV-infected older adults already on HIV treatment.
详细描述
The primary objective of this study is to compare 8-week changes in circulating levels of malondialdehyde (MDA), circulating levels of F2-isoprostanes, and flow-mediated dilation (FMD) of the brachial artery in older HIV-infected adults already receiving virologically suppressive antiretroviral therapy (ART) who are then randomized to either NAC 900 mg twice daily, NAC 1800 mg twice daily, or placebo. The relative efficacy and safety of these two doses of NAC will be assessed.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •HIV-1 infection, documented by (1) any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by a licensed Western blot or a second antibody test by a method other than the initial rapid HIV and/or E/CIA, or (2) by two detectable HIV-1 antigens, or (3) two detectable plasma HIV-1 RNA viral loads.
- •Age equal to or greater than 50 years.
- •Receipt of antiretroviral therapy of any kind for at least 6 months prior to screening.
- •HIV-1 RNA level < 75 copies/mL at screening.
- •For women who are still of reproductive potential, a negative urine pregnancy test at screening and willingness to use two forms of birth control during the course of the study. Acceptable forms of birth control include condoms (with or without a gel that can kill sperm), a diaphragm or cervical cap (with or without a gel that can kill sperm), an intrauterine device (IUD), or hormonal-based birth control ("the pill").
排除标准
- •Inability to complete written, informed consent.
- •Incarceration at the time of any study visit.
- •Known allergy or intolerance to n-acetylcysteine.
- •Use of n-acetylcysteine within 180 days of screening.
- •Diagnosed vascular disease (history of angina pectoris, coronary disease, peripheral vascular disease, cerebrovascular disease, aortic aneurysm, or otherwise known atherosclerotic disease).
- •History of congestive heart failure even if currently compensated.
- •History of portal hypertension or hepatic cirrhosis (either clinically diagnosed or histologically diagnosed).
- •Diagnosed disease or process, besides HIV infection, associated with increased systemic inflammation (including, but not limited to, systemic lupus erythematosis, inflammatory bowel diseases, other collagen vascular diseases).
- •Known or suspected malignancy requiring systemic treatment within six months of screening.
- •History of ADA-defined diabetes mellitus (115)
- •History of migraine headaches.
- •History of Raynaud's phenomenon.
- •History of cardiac arrhythmias or cardiomyopathy.
- •Uncontrolled hyperthyroidism or hypothyroidism, defined as TSH values outside of the local reference range on most recent clinical assessment.
- •Asthma or COPD requiring daily use of beta-2-agonist therapy (e.g. albuterol)
- •History of carotid bruits.
- •Creatinine clearance < 50 mL/min (using the Cockcroft-Gault equation) using a serum creatinine level measured at screening.
- •Hemoglobin < 9.0 g/dL at screening.
- •Alanine aminotransferase (ALT) level or aspartate aminotransferase (AST) > 3 times ULN at screening.
- •Total bilirubin > 2.5 times ULN at screening; if the participant is receiving atazanavir, then s/he would be excluded if total bilirubin is > 3.5 times ULN at screening.
- •Therapy for serious medical illnesses within 14 days prior to screening.
- •Pregnancy or breastfeeding during the course of the study.
- •Uncontrolled hypertension, defined as systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg at screening.
- •Receipt of investigational agents, cytotoxic chemotherapy, systemic glucocorticoids (of any dose), or anabolic steroids at screening.
- •Previous receipt of stavudine or didanosine for more than 7 cumulative days.
- •Receipt of daily Vitamin C or Vitamin E supplements at screening.
- •Alcohol intake more than the equivalent of one 8 oz. of wine daily for the 7 days prior to screening.
- •Active drug use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements.
结局指标
主要结局
Change in Circulating F2-isoprostane Levels
时间窗: Baseline and 8 weeks
Oxidative stress measure
Change in Flow-mediated Dilation (FMD) of the Brachial Artery
时间窗: Baseline and 8 weeks
Measure of endothelial function
Change in Circulating Malondialdehyde Levels
时间窗: Baseline and 8 weeks
Measure of oxidative stress
次要结局
未报告次要终点
研究者
Samir K Gupta, MD, MS
Associate Professor of Medicine
Indiana University
研究点 (2)
Loading locations...
相似试验
终止
不适用
N-AcetylCysteine vs. Placebo to Prevent Neurotoxicity Induced by Platinum Containing ChemotherapyCarcinoma, Non-Small-Cell LungCarcinoma, Small Cell LungMesotheliomaNCT00637624Rijnstate Hospital69
已完成
早期 1 期
Defining N-Acetyl Cysteine as a Treatment for Inhibiting Prurogenic StimuliSkin DisorderPruritusNCT05287724Wright State University20
尚未招募
2 期
Use of N-Acetylcysteine in the Treatment of Repetitive and Self-Injurious Behaviors in Cornelia de Lange SyndromeCornelia de Lange SyndromeNCT04381897Johns Hopkins University10
已完成
2 期
A Trial of N-Acetylcysteine (an Over-the-Counter Medicine) in Adolescents Who Smoke MarijuanaCannabis DependenceNCT01005810Medical University of South Carolina116
已完成
2 期
Clinical Trial for Alcohol Use Disorder and Post Traumatic Stress Disorder (PTSD)Post Traumatic Stress Disorder (PTSD)Alcohol AbuseAddictionNCT02966873Medical University of South Carolina182